Repros Therapeutics plans $10 million at-the-market offering of stock

Agent Ladenburg Thalmann assists; deal finances corporate purposes

By Devika Patel

Knoxville, Tenn., Aug. 9 – Repros Therapeutics Inc. negotiated a $10 million at-the-market equity offering with agent Ladenburg Thalmann & Co. Inc. on Aug. 9, according to an 8-K and prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Ladenburg Thalmann will be paid a 2% commission.

Proceeds will be used for general corporate purposes, including research and development, sales and marketing initiatives, general and administrative expenses, working capital and capital expenditures.

Based in The Woodlands, Texas, Repros develops drugs for the treatment of reproductive disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.